17 results about "RGD peptide" patented technology

The invention discloses a PNA-based pre-targeting probe as well as a preparation method and application thereof. The pre-targeting probe based on the PNA comprises a pre-targeting receptor probe PNA-EB-RGD and a ligand probe cPNA labeled by radionuclide, in the PNA-EB-RGD, the PNA is peptide nucleic acid, the EB is Evans blue, and the RGD is RGD peptide; the cPNA is a complementary sequence of the PNA. The PNA-based pre-targeting probe provided by the invention can reduce systemic circulation radiation exposure, obviously reduce blood toxicity and slow down tumor growth.

The invention provides a molecular interaction network protection system based on structural biology and an optimization method thereof, and relates to the technical field of biotechnology and molecular engineering.The molecular interaction network protection system comprises a USAG-1 protein binding domain, and the USAG-1 protein binding domain comprises a Glu32-Arg58-Ser76 hydrogen bond network and a Phe41 / Trp65 / Leu83 hydrophobic core; the MMP-9 cleavage site mutant is used for carrying out 20 substitutions from D to N / V / A in the PLGLA sequence, and is combined with G52S mutation; the ellipticity of the CD spectrum of the RGD peptide at 222nm is less than or equal to-15 mdeg, and the RGD peptide comprises a salt bridge at the i / i + 4 position. The USAG-1 protein binding domain also comprises an Asn45 carbohydrate chain, and the molecular weight of the Asn45 carbohydrate chain is 500 to 2000 Da. The phi angle of the RGD peptide is-57 + / -5 degrees, and the psi angle of the RGD peptide is-47 + / -5 degrees. According to the invention, through a multi-dimensional structure locking strategy, while the functional activity of biomolecules is maintained, accurate control of alpha-helical conformation is realized, a resistance mutation library is constructed, and the fundamental contradiction of stability-activity imbalance, conformation control misalignment and single-point mutation drug resistance in the traditional technology is thoroughly solved.

This invention discloses an arginine-glycine-aspartic acid (RGD) peptide-modified chiral atomically precise metal nanoclusters, their preparation, and applications. The RGD peptide-modified chiral atomically precise metal nanoclusters consist of an atomically precise metal core, a chiral RGD peptide ligand layer, and linking molecules connecting the metal core and ligand layer. The chiral regulation and targeting functions of the RGD peptide-modified chiral atomically precise metal nanoclusters synergistically enhance their targeting and penetration at the tissue and cellular levels, thereby improving their uptake efficiency. After optimization with α... v The binding constant of β3 integrin is 1.4 × 10⁻⁶. ‑6 M ‑1 RGD peptides modify the ultrasmall metal cores of chiral atomically precise metal nanoclusters, endowing them with highly efficient and rapid renal clearance properties. This invention provides a solution suitable for various α-cell tumors, arthritis, liver fibrosis, and other conditions. v RGD peptides modified with chiral atomic precision metal nanoclusters, used to treat diseases with high expression of β3 integrin, can achieve efficient enrichment at target sites for imaging.

The invention belongs to the technical field of biomedical materials, and particularly relates to an intelligent delivery patch based on epidermal stem cell adhesion regulation and a preparation method of the intelligent delivery patch. The intelligent delivery patch is prepared from the following raw materials in parts by weight: 1-5 parts of a drug-loaded compound, 8-15 parts of methacrylated gelatin, 0.5-2 parts of an enzyme response cross-linking agent, 0.3-1.5 parts of a force sensitive linking ligand, 0.1-1 part of a cell adhesion ligand and 0.05-0.2 part of LAP, drug-loaded nanoparticles of which the surfaces are modified with beta-cyclodextrin are anchored through a hydrogel network containing an azobenzene group, MMP sensitive peptide and RGD peptide, and the drug-loaded nanoparticles and the RGD peptide are combined to form the intelligent delivery patch. Efficient capture and enzyme response desorption of epidermal stem cells are achieved through synergism of MMP sensitive peptide and RGD peptide, a force sensitive release system is constructed through a supramolecular subject and object formed by beta-cyclodextrin and azobenzene, long-acting delivery is achieved by responding to mechanical stimulation while burst release of drugs is inhibited, and wound repair is promoted synergistically.

The invention discloses an active tumor targeting micelle based on RGD (arginine-glycine-aspartic acid) peptide as well as a preparation method and application of the active tumor targeting micelle. The invention provides a compound as shown in a formula (I) and pharmaceutically acceptable salts thereof. The nano-micelle containing the compound as shown in the formula (I) is high in drug loading capacity, small in particle size, spherical in shape, uniform in size and simple and convenient to prepare and operate, shows an excellent tumor targeting effect and good biological safety in vivo and in vitro, and has a good application prospect. (I)

The invention relates to the technical field of biological medicine, and provides cascade response type nanoparticles for adenomyosis and a preparation method thereof. The core of the system is nanoparticles constructed based on a carrier PLGA-(S-S-PPS) 2, and the disulfide bond of the carrier can be specifically broken and disintegrated in high-concentration H2O2 of a focus. The nanoparticles are loaded with a pH responsive fluorescent-ketal-berberine prodrug, ketal bonds are hydrolyzed in an acidic microenvironment, and berberine is released to realize fluorescence visualization. Hyaluronidase is encapsulated in the nanoparticles and is used for degrading a hyaluronic acid matrix. The surface modified RGD peptide can be specifically combined with integrin alpha v beta 3 to realize active targeting. The synergistic action mechanism of the system is as follows: RGD-mediated targeted accumulation, the carrier disintegrates and releases the content under H2O2, hyaluronidase degrades the matrix to enhance permeation, the prodrug releases berberine in an acid environment, and cell proliferation is synergistically inhibited and angiogenesis is reduced. Experiments prove that the hydrogel has good ROS / pH / enzyme responsiveness, fluorescence visualization, targeted accumulation, high drug loading rate (18.7%) and biological safety.

The application discloses a periodontitis targeted sustained-release gel based on epithelial training immunity and a preparation method thereof, relates to the technical field of biological medicine, and the preparation process is as follows: poloxamer is modified and then dissolved in anhydrous acetonitrile; RGD peptide is dissolved in a PBS buffer solution, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide are added for activation to obtain an activated RGD peptide solution; the activated RGD peptide solution is added into the modified poloxamer solution, and reaction is carried out at room temperature to obtain RGD peptide modified poloxamer; the RGD peptide modified poloxamer solution is mixed with a beta-glucan solution and a TLR2 agonist solution to obtain the periodontitis targeted sustained-release gel. The gel provided in the application can specifically target gingival epithelial cells, reduce inflammatory reactions, promote periodontal tissue regeneration, has good biocompatibility and sustained-release performance, and can effectively control periodontitis and prevent recurrence.

The invention relates to the technical field of biomedical engineering and regenerative medicine, and particularly discloses PRP composite gel. Comprising a component A and a component B, wherein the component A comprises a temperature-sensitive block copolymer matrix, a component B and a component C, the temperature-sensitive block copolymer matrix is prepared from Pluronic F-127 (the mass fraction is 20-25%) and methacrylic anhydride gelatin (GelMA (the mass fraction is 5-8%), and the methylacryloylation degree of the GelMA is 60-70%; the functionalized magnetic nanoparticles are characterized in that RGD peptides (the grafting rate is greater than or equal to 0.5 mu g / mg) are grafted on the surfaces of superparamagnetic Fe3O4 coated SiO2 nanoparticles (the particle size is 50 + / -5nm, and the thickness of a SiO2 coating layer is 8-10nm), and the mass fraction is 0.05-0.1%; the invention further provides an injection system and an injection method. According to the invention, the temperature-sensitive gel, the magnetic targeting PRP and the electromagnetic synergistic injection system are organically combined, so that the synergistic unification of three seemingly contradictory technical requirements of'fine needle injection '(27G), 'instant gelation' (completed within 3 seconds) and'directional slow release 'is successfully realized, and a major breakthrough is made technically.

The invention relates to the technical field of medicine materials, in particular to preparation of a novel diterpenoid nano-material and application of the novel diterpenoid nano-material in treatment of glioblastoma, the novel diterpenoid nano-material comprises longkaurin A, lipidosome and mesoporous silica nanoparticles, and the mass ratio of longkaurin A to lipidosome to mesoporous silica nanoparticles is (1-2): (5-11): (3-4). The surface of the liposome is modified with a targeting ligand, and the ligand is selected from at least one of folic acid, RGD peptide and an antibody. The prepared novel diterpenoid nano material solves the clinical bottleneck of poor druggability of natural diterpenoid drugs, and perfectly balances high drug loading capacity and high biocompatibility / long circulation. The longlikaurin A is applied to treatment of glioblastoma, proliferation of microglioblastoma cells can be remarkably inhibited, tumor growth is remarkably inhibited in subcutaneous and in-situ intracranial xenograft models, the lifetime is prolonged, and the longlikaurin A has extremely high clinical transformation value.

The invention discloses a recombinant chimpanzee oncolytic adenovirus Adsimian-delta24-IL21 and a construction method and application thereof, the vector is based on serotype 25 chimpanzee adenovirus, the immunogenicity is reduced by deleting an E3 region, and the integrin targeting is enhanced by inserting an RGD peptide fragment; a skeleton plasmid pAdsimian-deltaE3 is in seamless cloning connection with a shuttle plasmid pSRK17-delta24-CMV carrying delta24 mutation E1A, a recombinant oncolytic adenovirus Adsimian-delta24-IL21 and a control virus Adsimian-delta24-EGFP are constructed, the delta24 mutation enables the virus specificity to be copied in Rb defect tumor cells, the IL-21 gene remodels a tumor immune microenvironment by activating CD3 + / CD8 + T cells, and the tumor immune microenvironment of the Rb defect tumor cells is improved. The invention provides an efficient carrier and a method for oncolytic-immune combined treatment of colorectal cancer.

The invention discloses a pathological blood-brain barrier targeting nano preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicines.The nano preparation takes nanoparticles formed by assembling amphiphilic block copolymers as a carrier, RAP peptide and RGD peptide are co-modified on the surface of the carrier, and the nano preparation is prepared. The RAP peptide can specifically recognize and combine with an RAGE receptor highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptide also has the activity of blocking an RAGE-AB pathological pathway; the RGD peptide serves as an integrin binding motif, the endocytosis efficiency of the nanoparticle can be remarkably enhanced through the interaction with a cell surface integrin receptor, transfer of the nanoparticle to lysosome after endocytosis is promoted, and through the synergistic effect of the two ligands, the nanoparticle can be efficiently targeted to lesion cerebrovascular endothelium expressing RAGE and can also be efficiently targeted to the lesion cerebrovascular endothelium expressing RAGE. The RAGE protein can be effectively internalized and guided to the lysosome, so that the degradation of the RAGE protein is enhanced by virtue of a lysosome way while the targeted drug delivery is realized, and the active intervention on a key pathological pathway is realized.

The invention provides a sclera strengthening collagen peptide compound based on receptor targeting and enzyme response release and a preparation method thereof. The compound comprises (a) a core carrier, (b) sclera strengthening active peptide (SRAP), (c) an enzyme response connecting layer and (d) a receptor targeting ligand, wherein the receptor targeting ligand is modified on the outermost layer of the compound and is selected from RGD peptide or cyclic RGD peptide (cRGD). Through collaborative design of receptor targeting and enzyme response release, precise delivery and intelligent release of sclera-enhanced active peptide at a diseased region are realized, targeting, safety and treatment efficiency of the medicine are remarkably improved, and the key problems of short half-life period, poor targeting, uncontrollable release and the like of the traditional peptide medicine are effectively solved; the invention provides an efficient, stable and clinically convertible novel nano treatment strategy for precise intervention of progressive myopia.

The present invention relates to an imaging agent comprising a ZW700-1c dye conjugated to a cyclic-RGD peptide targeting ligand. The conjugate of the invention has superior stability and desirable in vivo properties as compared to other zwitterionic near-infrared contrast agents. The invention also relates to a method of imaging cells of a subject using the imaging agent. In particular, the invention relates to a method of imaging or identifying cells of a subject which are or are suspected of overexpressing one or more integrins using the imaging agent. Such cells include tumors, inflammatory cells, and cells undergoing angiogenesis.

The application discloses a preparation method of a PEDV COE subunit vaccine targeting M cells and application thereof. The application connects RGD peptide targeting M cells, a core neutralizing epitope COE region on a PEDV S protein and a fluorescent protein, expresses a recombinant protein, introduces a sulfur-containing amino acid into the protein to facilitate modification of the recombinant protein and connection of the protein to other substances in a covalent bond mode, and obtains a safe and effective mucosal subunit vaccine with green fluorescent labeling. Unlike common vaccines, the antigen of the vaccine can not only be directly taken by dendritic cells, but also be presented to dendritic cells through targeting M cells, the antigen presentation efficiency is significantly improved, the downstream immunity is more effectively started, and a series of immune responses of the body are induced, so that the mucosal immune system of the body produces a large number of PEDV specific antibodies to resist invasion of external pathogens, and the effect of specific immune protection is achieved.

The present invention relates to methods of imaging adenomyosis using the radiopharmaceutical agent 99mTc-maraciclatide. The technetium-99m radiopharmaceutical is suitably prepared from a non-radioactive kit containing the RGD peptide maraciclatide. Also described are methods of diagnosis, therapy selection and therapy monitoring of adenomyosis using the agent. The invention also includes the use of the kit and / or gamma camera or gamma detector in the methods of the invention.

The present application relates to the field of hydrogel, in particular to an antibacterial medical hydrogel and its preparation method and application. The raw materials of the hydrogel include tri-lysine, functional polypeptide, multi-arm-polyethylene glycol derivative and polyethyleneimine, wherein the amino acid sequence of the functional polypeptide includes RGD peptide and the polypeptide described in SEQ ID NO. 1. The hydrogel has the effects of antibiosis and promoting fibroblasts by adding the functional polypeptide, which is beneficial to the healing of wounds and has a wide application prospect in wound sealing.

The application discloses a pathological blood-brain barrier targeting nano-preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicine. The nano-preparation takes nanoparticles assembled by an amphiphilic block copolymer as a carrier, and is co-modified with RAP peptides and RGD peptides on the surface. The RAP peptides can specifically recognize and bind to the RAGE receptor which is highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptides also have the activity of blocking the RAGE-AB pathological pathway. The RGD peptides serve as an integrin binding motif, can significantly enhance the endocytosis efficiency of the nanoparticles through the interaction with the cell surface integrin receptor, and promote the transportation of the nanoparticles to lysosomes after endocytosis. Through the synergistic effect of the two ligands, the nanoparticles can not only be efficiently targeted to the diseased brain vascular endothelium expressing RAGE, but also be effectively internalized and guided to lysosomes, so that the targeted drug delivery is realized, the degradation of the RAGE protein is enhanced by means of the lysosome pathway, and the active intervention on the key pathological pathway is realized.